Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluorodopa F 18 is a radiopharmaceutical diagnostic agent used in positron emission tomography (PET) imaging. It is an amino acid analog of fluorodopa labeled with the positron-emitting isotope fluorine F 18. The drug is designed to cross the blood-brain barrier and be taken up by dopaminergic nerve terminals in the striatum. Once inside, it is decarboxylated by amino acid decarboxylase to fluorodopamine, which is then stored in presynaptic vesicles. The radioactive decay of Fluorine-18 allows for the visualization of these dopaminergic pathways via PET scans, aiding in the evaluation and diagnosis of adult patients with suspected Parkinsonian syndromes and other neurological conditions. It also has potential as a tumor tracer for various cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fluorodopa F 18.